Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcoma by Devenish, CJ et al.
Title
Loss of ATRX and DAXX expression identifies poor prognosis
for smooth muscle tumours of uncertain malignant potential and
early stage uterine leiomyosarcoma
Author(s)
Slatter, TL; Hsia, H; Samaranayaka, A; Sykes, P; Clow, WB;
Devenish, CJ; Sutton, T; Royds, JA; Ip, PCP; Cheung, ANY;
Hung, NA
Citation Journal of Pathology, 2015, v. 1, p. 95-105
Issued Date 2015
URL http://hdl.handle.net/10722/232168
Rights
Journal of Pathology. Copyright © John Wiley & Sons.; This
work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License.
Loss of ATRX and DAXX expression identifies poor prognosis for
smooth muscle tumours of uncertain malignant potential and
early stage uterine leiomyosarcoma
Tania L. Slatter,1 Howard Hsia,1 Ari Samaranayaka,2 Peter Sykes,3 William (Bill) Clow,4,† Celia J. Devenish,4
Tim Sutton,5 Janice A. Royds,1 Philip PC Ip,6 Annie N. Cheung6 and Noelyn Anne Hung1*
1Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
2Department of Preventive and Social Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
3Department of Obstetrics and Gynaecology, University of Otago, Christchurch, New Zealand
4Department of Women’s and Children’s Health, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
5 Anatomical Pathology Service, Pathlab Bay of Plenty, Tauranga, New Zealand
6 Anatomical Pathology Services, Department of Pathology, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR
*Correspondence to: Noelyn Anne Hung, Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
e-mail: noelyn.hung@otago.ac.nz
†Deceased
Abstract
Uterine smooth muscle tumours of uncertain malignant potential (STUMP) are diagnostically and clinically chal-
lenging. The alternative lengthening of telomeres (ALT) telomere maintenance mechanism is associated with
poor survival in soft tissue leiomyosarcoma. Time to first recurrence and survival were known for 18 STUMP and
43 leiomyosarcomata (LMS). These were screened for ALT telomere maintenance by the presence of ALT-
associated PML bodies (APBs) and for changes associated with the ALT phenotype, namely aberrant p53 expres-
sion, isocitrate dehydrogenase 1 mutation (R132H substitution) expression, mutant ATRX (athalassemia/mental
retardation syndrome X-linked) expression and mutant DAXX (death-domain-associated protein) expression by
immunohistochemistry (IHC). Overexpression of p16INK4A was examined immunohistologically in a subset of
cases. Many of the tumours associated with death or recurrence demonstrated APBs commensurate with ALT
telomere maintenance. However, all uterine STUMP (4/4), and vaginal STUMP (2/2) patients, and almost all LMS
patients (88.4%, 23/26, including 90% (9/10) of stage 1 LMS cases), who had died of disease or who had recur-
rent disease, displayed loss of ATRX or DAXX expression. Loss of ATRX or DAXX expression identified poor prog-
nosis (95% CI 2.1 to 40.8, p<0.003), in the LMS group. Thus, loss of ATRX or DAXX expression in uterine
smooth muscle tumours identifies a clinically aggressive molecular subtype of early stage LMS and when histo-
pathological features are problematic such as in STUMP. As ATRX and DAXX IHC is readily performed in diagnos-
tic laboratories these are potentially useful for routine histopathological classification and management.
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Introduction
For nearly 50 years uterine smooth muscle tumours
fulfilling some, but not all, of the pathological criteria
for uterine leiomyosarcoma (LMS) have been diagnos-
tically and clinically challenging [1]. Smooth muscle
tumours of uncertain malignant potential (STUMP)
have histopathological features of malignancy falling
short of LMS, variably clinically aggressive course
and recurrence rates of 4.6% to 26.7% depending on
histopathological criteria employed [2]. These charac-
teristics have generated considerable management and
treatment uncertainty and necessitated prolonged peri-
ods of follow-up [1,3] At the molecular level, aberrant
immunohistochemical expression of p53 and p16INK4A
have been investigated as prognostic and diagnostic
tools and are correlated with poorer prognosis in some
studies [4]
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Telomere maintenance is an important aspect of
the replicative capacity inherent in neoplasia, and
telomerase inhibitors have been developed as poten-
tial targeted therapy [5]. In the normal cell, progres-
sive telomere shortening to a critical length occurs
until cell division ceases. This shortening is circum-
vented in neoplasia by the activation of telomere
maintenance [6]. Recent progress in the molecular
subtyping of mesenchymal tumours has identified
prognostic implications in the type of telomere main-
tenance mechanism employed. The presence of alter-
native lengthening of telomeres (ALT) maintenance
portends a better prognosis in glioblastoma multi-
forme compared with telomerase activation in these
tumours [7], but a worse prognosis in many soft tis-
sue sarcomata [8]. ALT maintenance has been dem-
onstrated in uterine LMS as a poor prognostic
indicator [9] [10]. ALT telomere maintenance
tumours may also respond differently to treatment,
especially radiotherapy [11].
ALT maintenance in pancreatic neuroendocrine
tumours and pediatric glioblastoma multiforme has
been shown to closely correlate with the presence of a
mutation in ATRX and DAXX genes [12,13]. In glio-
blastoma multiforme ALT tumours were associated
with simultaneous mutations in ATRX-DAXX, p53
and H3F3A [14]. The ATRX and DAXX proteins are
demethylases involved in remodeling of chromatin
structure. The alteration of chromatin architecture
through the inhibition of demethylation by ATRX and
DAXX dysfunction has been reported to underlie ALT
activation in gliomagenesis [14]. Isocitrate dehydro-
genase (IDH) mutations have also been identified in
association with ALT activation in tumours [15,16].
ALT TMM produces extremely long and heteroge-
neous telomere lengths and multiprotein structures
called ALT-associated PML bodies (APBs). Evalua-
tion of ALT by APB detection as well as ATRX and
DAXX immunohistochemistry (IHC) was conducted
to explore their development as reproducible histo-
pathological tools, thereby enhancing diagnosis and
predicting clinical progress of smooth muscle
tumours. The profile of the ALT associated R132H
IDH1 mutation was studied to provide a biological
basis for its application as a radiological diagnostic
and therapeutic tool.
We hypothesized that ALT telomere maintenance
identifies clinically aggressive tumours prone to recur-
rence and death and that ALT maintenance was an
early tumourigenic change. This would prove useful
for diagnostically difficult tumours (STUMP) and clin-
ically useful prior to emergent metastatic disease
(stage 1 LMS) for therapeutic management and
follow-up. Tumour protein p53 and p16INK4A IHC was
also studied to further define their diagnostic utility in
a larger cohort than had previously been examined.
Methods
Patients with uterine smooth muscle tumours at Dun-
edin and Tauranga Hospitals, New Zealand, and
Queen Mary Hospital, Hong Kong, were studied. Eth-
ical approval was obtained from the New Zealand
Health and Disabilities Lower South Regional Ethics
Committee. Clinical and pathological data regarding
patient’s age, tumour size, gross and histological fea-
tures, tumour stage, treatment and follow-up were
obtained from hospital notes and pathological reports.
Eleven cases of cellular or variant leiomyoma (LM),
16 cases of uterine STUMP, two cases of vaginal
smooth muscle tumour (fulfilling criteria for uterine
STUMP) and 43 cases of LMS were included. The
pathological sections were reviewed according to
established criteria [4], based on the presence of
necrosis, nuclear atypia, margin and mitotic activity.
Five of the variant LM were cellular and one was
mitotically active but without cytological atypia or
tumour cell necrosis. The presence of diffuse or mul-
tifocal moderate to severe cytologic atypia and <10
mitoses per 10HPFs, tumour cell necrosis but no
other worrisome features or >15 mitoses per 10HPFs
but no other worrisome features, defined each
STUMP case, and are illustrated in Figure 1. STUMP
case 6 was a mixed spindle and myxoid tumour with
mitotically active spindle cell component but with
low (<0/10HPF) mitotic count in the myxoid compo-
nent, and thus fell short of criteria for a myxoid
LMS. Similarly, case 8 was a mixed spindle and epi-
thelioid tumour, but with less than 50% epithelioid
component, thus falling short of criteria for an epithe-
lioid LMS [4]. As no criteria exist for the diagnosis
of a vaginal STUMP, we have applied the uterine
criteria to two vaginal cases in an effort to better
characterize these rare tumours. Seven of the 18
cases of STUMP had previously been reported by
two of us [2]. LMS were classified according to
WHO criteria [17].
IHC analyses
IHC reactions were performed using standard techni-
ques: paraffin embedded tissue sections, heat-mediated
antigen retrieval and antibody detection by EDL
(Dako, Glostrup, Denmark) and DAB according to the
manufacturers’ instructions. p53 expression was deter-
mined using DO-7 (Cell Marque, Rockin, CA) at a
1 in 50 dilution. p16INK4A was detected using 1 in
1000 dilution (2D9A12, Abcam, Cambridge, UK).
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Mutant IDH1 was detected using the anti-Human
IDH1 R132H specific mouse monoclonal antibody
HO-9 (Dianova, Hamburg, Germany) diluted 1 in 50.
ATRX was detected using HPA001906 (Sigma-
Aldrich, St Louis, MO) diluted 1 in 700. DAXX was
performed using a 1 in 100 dilution HPA008736
(Sigma-Aldrich, St Louis, MO). Cells were imaged
using light microscopy (DM 2000 microscope, DFC
295 camera and Application Suite software, version
3.5.0, Leica, Solms, Germany).
The slides were assessed by four surgical pathologists
(PI, AC, NH and TS) independently. A tumour was con-
sidered positive for p53 when either no tumour cell
staining was evident, or greater than 80% of the tumour
cells were positively stained. IDH1 was considered pos-
itive when 10% or more of the tumour nuclei were
moderately stained by IHC. IHC for p16INK4A expres-
sion was performed in a limited cohort of 36 cases (15/
18 STUMP and 24/43 LMS). Greater than 70% nuclear
staining at intensity greater than adjacent normal vascu-
lar smooth muscle was interpreted as p16INK4A, overex-
pression (Figure 2). Ten percent or less nuclear staining
in more than 50% of the tumour for ATRX or DAXX
protein determined loss of expression. Cell nuclei of
endothelial and vascular smooth muscle from normal
tissue in the sections served as an internal control for
ATRX or DAXX protein expression (thus normal cell
nuclear staining of these nuclei was expected within the
tumour, Figure 2).
APB detection
The APB detection method used in this study is a
modified version of the method used by Yeager et al.
(1999) and Henson et al. (2005) and our specific
methodology has been reported in earlier studies
[8,18,19]. Briefly, slides were incubated an anti-PML
rabbit polyclonal primary antibody (H-238, Santa
Cruz Biotechnology, Santa Cruz SD) using a 1 in
500 dilution and detected with an Alexa Fluor 488
antibody (Life Technologies, Carlsbad, CA). Telo-
mere DNA was detected using a Cy3-labelled PNA
probe 50-CCCTAACCCTAACCCTAA-30 (Life Tech-
nologies, Carlsbad, CA). The cellular nuclei were
stained using DAPI. Cells were imaged using confo-
cal microscopy (Zeiss LSM510; Carl Zeiss, Thorn-
wood, NY). For each colocalized signal, the
fluorescent signal from each channel was analysed
using the software Zeiss LSM Image Examiner (Ver-
sion 30115; Carl Zeiss Thornwood, NY). A tumour
was designated APB positive when a colocalized
focus of telomeric DNA and PML protein within the
Figure 1. A to C: Three cases of STUMP that were followed by a recurrence. These have moderate to high cellularity, multifocal mod-
erate atypia and <or=<10 mitoses/10 HPFs. D: Leiomyosarcoma with marked atypia and tumour cell necrosis.
Poor prognosis uterine smooth muscle tumours 97
VC 2015 John Wiley and Sons Ltd and The Pathological Society of Great Britain and Ireland J Path: Clin Res April 2015; 1: 95–105
nucleus was identified in 5% of the cells. One APB
in a cell nucleus qualified the cell as positive. APBs
were interpreted as bright yellow colocalized areas
with a clear peak signal of at least 100 relative fluo-
rescent intensity (Figure 2).
Statistical analyses
Correlations between categorical variables were ana-
lysed with the v2 test with p< 0.05 taken as statisti-
cally significant. Descriptive statistics of patients and
their tumours, and the frequencies of observing each
variant (i.e., prospective marker) among patients in
each tumour cohort were prepared. The risk of out-
come event among patients with each marker was
estimated using univariate Cox regression. Cases
with unknown outcome status were considered as
censored in these time-to-event analyses.
Results
The clinical characteristics of the cases are summar-
ized in Table 1. Patients with LM were treated by hys-
terectomy or surgical excision alone. None of these
patients had a recurrence. Patients with a STUMP
diagnosis underwent hysterectomy or surgical excision
alone (one case underwent myomectomy only). None
Figure 2. FISH and immunohistochemical staining of uterine smooth muscle tumours. (A) Aberrant p53 expression in a tumour. (B)
p16INK4A overexpression in a tumour. (C) IDH1 (isocitrate dehydrogenase 1) mutation (R132H substitution) immunopositive tumour.
(D) Left, ATRX (a thalassemia/mental retardation syndrome X-linked) immunonegative tumour (indicative of loss of expression and
surrogate for ATRX mutation). Positive staining is present in associated normal cells (endothelial cells are highlighted with a black
arrow). Right, immunopositive ATRX staining (no loss of expression and surrogate for no ATRX mutation). (E) Left, DAXX (DAXX
death-domain-associated protein) immunonegative tumour (indicative of loss of expression and surrogate for DAXX mutation). Posi-
tive staining is present in associated normal cells (positive staining in endothelial cells is highlighted with a black arrow). Right,
immunopositive DAXX staining (no loss of expression and surrogate for no DAXX mutation). (F) Co-localisation of telomere FISH and
IHC for promyelocytic protein to detect ALT-associated PML bodies (APBs). Top left, PML immunofluorescence (green), Top right telo-
mere fluorescence in situ hybridisation (FISH) (red), bottom left DAPI nuclear stain (blue), bottom right combined images. Bottom
images, identification of colocalized PML – immunofluorescence image and telomere FISH intensity graph.
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of the patients with a uterine STUMP diagnosis
received radiation or chemotherapy at the time of diag-
nosis. In this cohort four women (25%) had first recur-
rence at mean 49 months, and three women (18.7%)
had died of disease at 56, 60 and 140 months post
diagnosis. In the LMS cohort, nearly half of the
women (49%) had a recurrence or had died, with mean
recurrence or death at 32 months. However, the longest
recurrence-free survival was 11 years (case 13).
The follow-up period totaled 2567 person-months
without recurrence, 1243.5 person-months with recur-
rence, 2742 person-months death not observed and
1199.5 person-months among patients who died of dis-
ease. The STUMP cases were followed for a mean of
70 months (median 58 months, range 1–140 months)
until recurrence or death, and 85.4 months (median 85
months, range 6–168 months) for no evidence of dis-
ease. The LMS cases were followed a mean of 35
months (median 22 months, range 1–138 months) until
recurrence or death, and 78 months (median 78 months,
range 1–156 months) for no evidence of disease. The
uterine STUMP cases recurred later (mean 49 months,
95% CI 47, 51) compared to recurrent LMS cases
(mean 22.3 months, 95% CI 6, 38, p5 0.02), but both
succumbed in a similar period (STUMP 76 months,
95% CI 9, 143 versus LMS mean 98 months, 95% CI
78–117, p5 0.07). For patients who presented in stage
1 LMS at diagnosis (n5 23), 35% had died by 10 years
follow-up (114 months) and two patients were alive
with disease at 23 and 78 months follow-up.
In the STUMP cohort the predominant histopatho-
logical type was spindle cell, except for two mixed
spindle cases (with <50% area of epithelioid compo-
nent, and myxoid admixed). The LMS cases were also
predominantly spindle cell type (72%, with epithe-
lioid, myxoid or mixed types in the remaining). Nei-
ther age nor tumour size was significantly different
between the STUMP and LMS cases (p5 0.10 and
p5 0.18). The mitotic rate, however, was significantly
lower in the STUMP group (p< 0.0001) as expected
with required diagnostic criterion of less than 10 mito-
ses per 10HPF. The individual features are given in
Tables 2 and 3.
All tumours were screened for APB presence, p53
aberrant expression (a surrogate for p53 mutation),
IDH1 R132H mutation expression and ATRX or
DAXX expression loss to determine the ALT pheno-
type. A subset of 24 LMS and 15 STUMP were also
screened for p16INK4A overexpression by IHC. We
refer to each of these as the molecular variants. No
molecular variant was identified as specific to the
spindled, epithelioid or myxoid subtypes. Examples
of p16INK4A overexpression, p53 expression, IDH1
R132H mutation expression, loss of expression of
ATRX or DAXX, no loss of expression for ATRX or
DAXX (no evidence of mutation), and APB presence
determination are given in Figure 2A–F. None of the
LM cases demonstrated a molecular variant, except
for one case with IDH1 R132H mutation expression.
The ALT phenotype was found in STUMP and LMS
but not in LM or variant LM cases
Amongst the 22 STUMP and LMS cases that were ALT
positive as determined by APB presence, 20 had ATRX
or DAXX loss (p< 0.0001). Thus, ALT was highly
associated with ATRX and DAXX expression loss com-
mensurate with the presence of mutations. Only one
LMS case was APB positive with no loss of ATRX or
DAXX expression. Another 19.6% (12/61) of STUMP
and LMS showed ATRX or DAXX expression loss
without APB presence. Only three LMS cases were
DAXX negative and the remaining cases were ATRX
negative. No STUMP and 14% (6/43) of LMS cases
showed IDH1 R132H mutation expression.
Table 1. Clinical details for the LM, STUMP and LMS cohorts
Leiomyoma Cellular/Mitotic Leiomyoma STUMP LMS
Number of patients 5 6 18 43
Mean age/years 50 49 44 47
Postmenopausal at presentation 2 (40%) 1 (16%) 3 (16%) 10 (23%)
Median tumour size cm 3.5 3.9 9 11
Extrauterine disease at presentation N/a N/a N/a 45%*
LMS Characteristics Stage n (%) Mean survival months Mean follow-up months
1 23 70.2 69.3
2 5 55.8 55.8
3 10 45.6 45.6
4 3 15.3 15.3
Missing 2 19.0 19
*One case unknown.
STUMP, Smooth muscle tumours of uncertain malignant potential;
LMS, Leiomyosarcoma,
N/a not applicable, n: number.
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ATRX or DAXX expression loss was associated
with older patient age, higher mitotic index and
cytological atypia
Overall, loss of ATRX or DAXX expression corre-
lated with older patient age (mean 51years CI
46.9, 55.0, versus mean 45 years, CI 41.4, 48.8,
p5 0.03), and a higher mitotic count (mean 14/
10HPF, CI 4.7, 11.3, versus mean 8/10HPF, CI
10.5, 17.2, p5 0.01). Similarly, diffuse or multifo-
cal moderate to severe cytological atypia was iden-
tified in 80% of tumours with ATRX or DAXX
expression loss, compared to only 56% of tumours
that maintained expression of either ATRX or
DAXX IHC. There was no correlation between his-
tological type and molecular markers. No correla-
tion was found with tumour size.
In STUMP and LMS, ATRX or DAXX expression loss
best predicted poor prognosis
All STUMP (6/6) patients and 23/26 (88.4%) LMS
patients, who had died or had recurrent disease,
had ATRX or DAXX expression loss in their
tumours. One patient of the three with neither
ATRX nor DAXX expression loss, also showed no
variation in any other molecular feature assessed,
and died at 77.5 months post diagnosis, aged 41
years (LMS case 8). One patient with an ALT pos-
itive, non-p53-aberrant tumour was without disease
at 156 months following resection of a polypoid
LMS, and this morphology may have contributed
to prolonged survival (LMS case 13).
For the LMS group, loss of ATRX expression
was found in all but three cases, which showed loss
of DAXX expression. In four cases, with loss of
neither ATRX nor DAXX expression, no disease
was yet evident at follow-up periods of 59, 66, 78
and 156 months. Patient outcomes are detailed in
Tables 2 and 3. At least one molecular variant was
found in the majority of tumours with recurrence or
death.
The STUMP group was too small for the statistical
analysis of survival. Univariate Cox regression
showed that, for overall survival in the LMS group,
loss of ATRX or DAXX expression identified poor
prognosis (CI 2.1 to 40, p< 0.003) and, for progres-
sion free survival, loss of ATRX or DAXX expres-
sion was statistically significant (CI 2.2 to 25,
p5 0.001). We were limited in our analysis of
p16INK4A IHC due to tissue availability but p16INK4A
overexpression was narrowly significant (CI, 0.3 to
0.9, p5 0.047). Aberrant p53 expression did not
reach significance.
Discussion
The homologous recombination based ALT mecha-
nism is found predominantly in mesenchymal malig-
nancies [20]. This is the largest study to date
examining ALT maintenance molecular markers with
recurrence and survival time in smooth muscle
tumours of the uterus. In particular, we examine early
stage LMS and tumours that are diagnostically
problematic.
Although APB determination is a well-tested
marker of ALT TMM, the detection method involves
combined FISH and IHC techniques, requiring partic-
ular expertise and time and some exceptions do occur
[19]. Furthermore, in our hands, APB presence was
not as significant as ATRX or DAXX expression
loss. ATRX or DAXX loss appears to occur early in
tumourigenesis and this could explain why some
tumours with ATRX or DAXX expression loss were
not ALT positive or p53 expression aberrant. The
association of ATRX or DAXX expression loss with
a higher proliferation rate (p5 0.0003) and pro-
nounced cytological atypia provides a molecular
basis for the histopathological assessment.
Immunohistochemical staining is widely used as a
surrogate for ATRX and DAXX mutation
[12,13,21,22]. This does not prove mutation and is
less sensitive on small-sized tissue microarrays com-
pared to sequence based methods to identify ATRX
mutations directly [22]. However, with awareness of
tumour heterogeneity, interpretation is straightfor-
ward and IHC is a practical test in the diagnostic
workup [12,13].
Tumours that lose ATRX or DAXX but maintain
wild-type p53 may respond better to DNA damaging
agents. In a recent study loss of ATRX sensitized
cells to 5-fluorouracil and cisplatin treatment by p53
mediated cell death [11]. In our study one uterine
STUMP and 14 LMS had loss of ATRX or DAXX
expression and wild-type p53 IHC expression, and
thus both recurrent STUMP and LMS could poten-
tially respond to DNA damaging treatment. However,
for patients with ATRX or DAXX expression loss,
the associated mutant p53 in their tumours may make
such treatment ineffective.
The acquisition of the R132H IDH1 mutation leads
to an alteration in catalytic ability and the production
of an oncometabolite, R(-)-2-hydroxyglutarate (2-HG)
that inhibits histone demethylases and indirectly
affects H3F3A methylation [23–25]. Furthermore, 2-
HG has been identified by noninvasive imaging [26],
and tumours with the mutant enzyme may be suscepti-
ble to chemotherapy [27]. The R132H IDH1 mutation
precedes mutation of p53, which appears to be the
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lynch pin facilitating recombination and the emer-
gence of the gross deregulated ALT telomere length
phenotype [28]. IDH1(R132H) status by IHC was not
informative in our cohort, but our analysis did not cap-
ture all mutations in IDH. Other mutations in the iso-
forms of IDH1 or IDH2 may be involved. The R132H
IDH1 mutation is the most prominent IDH1 mutation
in glioma [29,30], but in cartilaginous tumours other
mutations in IDH1 were more frequent than R132H
[31,32]. We identified IDH1 R132H mutation in a LM,
which has not been previously reported.
The use of p16INK4A IHC as a diagnostic marker
indicative of changes in the p16INK4A-cyclinD1-pRB-
E2F-cyclinE cell cycle control pathway has been
investigated in LMS and STUMP with mixed results
[2,33,34]. With no difference in proliferation between
the p16INK4A overexpressed and nonover-expressed
tumours, it is unlikely to reflect enhanced p16INK4A
function. In the absence of a known viral oncogene,
overexpression in these tumours probably reflects the
mutational or epigenetic status of the retinoblastoma
gene. Indeed, alterations of the retinoblastoma gene
locus play an important role in the pathogenesis of
LMS [35]. Understanding alterations in the p16INK4A
cell cycle control pathway will have treatment implica-
tions [35]. That p16INK4A overexpressing STUMP
were also associated with diffuse or multifocal moder-
ate to severe cytological atypia may reflect a greater
degree of genetic alteration compared to tumours that
were not overexpressing p16INK4A and validates the
use of cytological atypia in the histopathological
assessment. In practice, however, p16INK4A IHC is of
limited value in distinguishing between LM with
bizarre nuclei and STUMP containing diffuse, bizarre
cells, as this marker has also been expressed in a large
number of the former cases [34].
The two vaginal cases posed particular difficulties
diagnostically. In case 17, mild atypia accompanied 9/
10HPF mitoses and tumour cell necrosis. The presence
of necrosis alone is viewed with caution in this area
[17], and in addition to the mitotic rate (9/10HPF) this
tumour could have been considered malignant (unfortu-
nately tumour size was not available). The other vagi-
nal tumour (case 18) also demonstrated tumour cell
necrosis, but with low mitotic rate, small size (4.2 cm)
and mild atypia. Of note, neither tumour demonstrated
another molecular variant, such as p53 aberrant expres-
sion or p16INK4A overexpression. These tumours high-
light the importance of identifying specific criteria for
a specific tumour, in different anatomical sites, but also
suggest loss of ATRX or DAXX expression may prove
similarly prognostic as in uterine tumours.
In summary, in this uterine STUMP cohort we
show a statistically significant longer time to first
recurrence than LMS, but that both STUMP and
LMS cases with loss of ATRX or DAXX expression
succumb at a similar time. All STUMP and 88.5% of
LMS associated with death or recurrence displayed
loss of ATRX or DAXX expression, including 90%
of stage 1 LMS cases. Commensurate with poor
prognosis these tumours had a higher rate of mitotic
activity and diffuse or multifocal moderate to severe
cytological atypia. That loss of ATRX or DAXX
expression is a stronger diagnostic marker than APB
presence suggests that demethylase loss occurs prior
to APB induction in tumourigenesis. Determination
of ATRX or DAXX expression by IHC in smooth
muscle tumours is readily applicable diagnostically
and these markers are potentially useful for histopath-
ological classification and clinical management.
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